ALNYLAM PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ALNYLAM PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.04B | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $844.29M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $492.85M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $219.75M | Feb 10, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.25B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.83B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.04B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $844.29M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $163.56M | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | $125.85M | Feb 11, 2021 |
| FY2020 | Jun 30, 2020 | $103.96M | Feb 11, 2021 |
| FY2020 | Mar 31, 2020 | $99.48M | Feb 11, 2021 |
| FY2020 | Dec 31, 2019 | $71.68M | Feb 11, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $100.04M | Feb 18, 2011 |
| FY2010 | Dec 31, 2009 | $100.53M | Feb 18, 2011 |
| FY2010 | Dec 31, 2008 | $96.16M | Feb 18, 2011 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $313.75M | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | $202.20M | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | ($90.48M) | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | ($18.25M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($278.16M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($440.24M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($1.13B) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | ($852.82M) | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | ($243.54M) | Feb 11, 2021 |
| FY2020 | Sep 30, 2020 | ($253.29M) | Feb 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $501.58M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($176.89M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($282.18M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($785.07M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | ($708.65M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($828.44M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($939.43M) | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | ($814.67M) | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | ($500.09M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | ($424.59M) | Feb 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.32B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.13B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.00B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $883.02M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $792.16M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $654.82M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $655.11M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $505.42M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $390.64M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $382.39M | Feb 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $975.53M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $795.65M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $770.66M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $620.64M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $588.42M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $479.01M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $382.36M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $199.37M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $89.35M | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $524.08M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($8.31M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $104.16M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($541.27M) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | ($641.69M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($614.96M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($278.43M) | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | ($562.62M) | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | ($382.79M) | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | ($307.70M) | Feb 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.70M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $34.28M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $62.21M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $72.06M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $76.37M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $70.36M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $140.16M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $126.89M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $104.21M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $64.56M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.97B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.24B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.83B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.55B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.64B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $3.41B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $2.40B | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.57B | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.99B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.26B | Feb 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.18B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.17B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.05B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.70B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.06B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.39B | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | $956.44M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | $272.84M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | $228.30M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $342.59M | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $789.18M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $67.09M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($220.64M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | ($158.22M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | $588.20M | Feb 13, 2025 |
| FY2023 | Dec 31, 2020 | $1.02B | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | $1.44B | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $1.30B | Feb 10, 2022 |
| FY2020 | Dec 31, 2017 | $1.77B | Feb 11, 2021 |
| FY2019 | Dec 31, 2016 | $920.22M | Feb 13, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.70B) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($7.29B) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($7.01B) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($6.57B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($5.44B) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($4.59B) | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | ($3.73B) | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | ($2.84B) | Feb 13, 2020 |
| FY2019 | Dec 31, 2017 | ($2.15B) | Feb 13, 2020 |
| FY2017 | Dec 31, 2016 | ($1.66B) | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $966.43M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $812.69M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $866.39M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $819.98M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $496.58M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $547.18M | Feb 10, 2022 |
| FY2020 | Dec 31, 2018 | $420.15M | Feb 11, 2021 |
| FY2019 | Dec 31, 2017 | $645.36M | Feb 13, 2020 |
| FY2018 | Dec 31, 2016 | $193.62M | Feb 14, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (9) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (7) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (8) | Feb 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 12, 2026 |
| FY2025 | Sep 30, 2025 | 1 | Feb 12, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (9) | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | (7) | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (7) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (8) | Feb 10, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 132.38M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 129.29M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 125.79M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 123.93M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 120.18M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 116.43M | Feb 10, 2022 |
| FY2020 | Dec 31, 2019 | 112.19M | Feb 11, 2021 |
| FY2019 | Dec 31, 2018 | 101.18M | Feb 13, 2020 |
| FY2018 | Dec 31, 2017 | 99.67M | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | 85.94M | Feb 15, 2018 |